Search hospitals > Minnesota > Duluth
Saint Luke's Hospital of Duluth
Claim this profileDuluth, Minnesota 55805
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Prostate Cancer
77 reported clinical trials
4 medical researchers
Summary
Saint Luke's Hospital of Duluth is a medical facility located in Duluth, Minnesota. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Prostate Cancer and other specialties. Saint Luke's Hospital of Duluth is involved with conducting 77 clinical trials across 171 conditions. There are 4 research doctors associated with this hospital, such as Homam Alkaied, Steven R. Bonin, Gretchen Karstens, MD, and Scott Mikesell, DO.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Breast Cancer
Global LeaderHER2 positive
ER positive
PR positive
Top PIs
Homam AlkaiedSaint Luke's Hospital of Duluth2 years of reported clinical research
Studies Cancer
Studies Lung Cancer
13 reported clinical trials
20 drugs studied
Steven R. BoninSaint Luke's Hospital of Duluth1 year of reported clinical research
Studies Small Cell Lung Cancer
Studies Cancer
7 reported clinical trials
21 drugs studied
Gretchen Karstens, MDSt. Luke's Hospital2 years of reported clinical research
Studies High Cholesterol
Studies Genetic Disorders
1 reported clinical trial
1 drug studied
Scott Mikesell, DOSt. Luke's Hospital of Duluth3 years of reported clinical research
Studies Atherosclerosis
1 reported clinical trial
2 drugs studied
Clinical Trials running at Saint Luke's Hospital of Duluth
Breast Cancer
Non-Small Cell Lung Cancer
Cancer
Lung Cancer
Pancreatic Carcinoma
High Cholesterol
Prostate Cancer
Neuroendocrine Carcinoma
Pancreatic Cancer
Adenocarcinoma
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Saint Luke's Hospital of Duluth?
Saint Luke's Hospital of Duluth is a medical facility located in Duluth, Minnesota. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Prostate Cancer and other specialties. Saint Luke's Hospital of Duluth is involved with conducting 77 clinical trials across 171 conditions. There are 4 research doctors associated with this hospital, such as Homam Alkaied, Steven R. Bonin, Gretchen Karstens, MD, and Scott Mikesell, DO.